HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders

Blood

Volumn 124, Issue 5, 2014, Pages 822-826

  Bertaina, Alice ^a   Merli, Pietro ^a   Rutella, Sergio ^a,b   Pagliara, Daria ^a   Bernardo, Maria Ester ^a   Masetti, Riccardo ^c   Pende, Daniela ^d   Falco, Michela ^e   Handgretinger, Rupert ^f   Moretta, Francesca ^a   Lucarelli, Barbarella ^a   Brescia, Letizia P ^a   Pira, Giuseppina Li ^a   Testi, Manuela ^g   Cancrini, Caterina ^h   Kabbara, Nabil ⁱ   Carsetti, Rita ^a   Finocchi, Andrea ^h   Moretta, Alessandro ^j   Moretta, Lorenzo ^e   Locatelli, Franco ^a,k   more..

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e G GASLINI INSTITUTE   (Italy)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^h UNIVERSITY OF ROME TOR VERGATA   (Italy)

ⁱ RAFIC HARIRI UNIVERSITY HOSPITAL   (Lebanon)

^j UNIVERSITY OF GENOA   (Italy)

^k UNIVERSITY OF PAVIA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ALLOGRAFT; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; EX VIVO STUDY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; IMMUNOPROPHYLAXIS; MALE; MORTALITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION;

ALLOGRAFTS; ANTIGENS, CD; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LYMPHOCYTE DEPLETION; MALE; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RETROSPECTIVE STUDIES; T-LYMPHOCYTES;

EID: 84905095192     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-563817     Document Type: Article

References (26)

1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813-1826.
2. Rocha V, Locatelli F. Searching for alternative hematopoietic stem cell donors for pediatric patients. Bone Marrow Transplant. 2008;41(2):207-214. (Pubitemid 351188919)
3. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339(17):1186-1193. (Pubitemid 28482127)
4. Locatelli F, Pende D, Maccario R, Mingari MC, Moretta A, Moretta L. Haploidentical hemopoietic stem cell transplantation for the treatment of highrisk leukemias: how NK cells make the difference. Clin Immunol. 2009;133(2):171-178.
5. Martelli MF, Aversa F, Bachar-Lustig E, et al. Transplants across human leukocyte antigen barriers. Semin Hematol. 2002;39(1):48-56. (Pubitemid 34081156)
6. Zecca M, Strocchio L, Pagliara D, et al. HLA-haploidentical T cell-depleted allogeneic hematopoietic stem cell transplantation in children with Fanconi anemia. Biol Blood Marrow Transplant. 2014;20(4):571-576.
7. Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari MC, Moretta A. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood. 2011;117(3):764-771.
8. Reisner Y, Hagin D, Martelli MF. Haploidentical hematopoietic transplantation: current status and future perspectives. Blood. 2011;118(23):6006-6017.
9. Chaleff S, Otto M, Barfield RC, et al. A large-scale method for the selective depletion of alphabeta T lymphocytes from PBSC for allogeneic transplantation. Cytotherapy. 2007;9(8):746-754. (Pubitemid 350226754)
10. Locatelli F, Bauquet A, Palumbo G, Moretta F, Bertaina A. Negative depletion of α/β+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation. Immunol Lett. 2013;155(1-2):21-23.
11. Martelli MF, Di Ianni M, Ruggeri L, et al. "Designed" grafts for HLA-haploidentical stem cell transplantation. Blood. 2014;123(7):967-973.
12. Locatelli F, Merli P, Rutella S. At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies. J Leukoc Biol. 2013;94(6):1141-1157.
13. Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116(14):2411-2419.
14. Christopeit M, Schütte V, Theurich S, Weber T, Grothe W, Behre G. Rituximab reduces the incidence of acute graft-versus-host disease. Blood. 2009;113(13):3130-3131.
15. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295-304.
16. Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med. 1983;98(4):461-466. (Pubitemid 13116613)
17. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
18. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706. (Pubitemid 29126745)
19. Inamoto Y, Flowers ME. Treatment of chronic graft-versus-host disease in 2011. Curr Opin Hematol. 2011;18(6):414-420.
20. Bacigalupo A, Socie' G, Lanino E, et al; Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party. Haematologica. 2010;95(6):976-982.
21. Driessen GJ, Gerritsen EJ, Fischer A, et al. Long-term outcome of haematopoietic stem cell transplantation in autosomal recessive osteopetrosis: an EBMT report. Bone Marrow Transplant. 2003;32(7):657-663. (Pubitemid 37258621)
22. Gaziev J, Sodani P, Lucarelli G, et al. Second hematopoietic SCT in patients with thalassemia recurrence following rejection of the first graft. Bone Marrow Transplant. 2008;42(6):397-404.
23. Sodani P, Isgrò A, Gaziev J, et al. Purified T-depleted, CD341 peripheral blood and bone marrow cell transplantation from haploidentical mother to child with thalassemia. Blood. 2010;115(6):1296-1302.
24. Fernandes JF, Rocha V, Labopin M, et al; Eurocord and Inborn Errors Working Party of European Group for Blood and Marrow Transplantation. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood? Blood. 2012;119(12):2949-2955.
25. Peffault de Latour R, Porcher R, Dalle JH, et al; FA Committee of the Severe Aplastic Anemia Working Party; Pediatric Working Party of the European Group for Blood and Marrow Transplantation. Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. Blood. 2013;122(26):4279-4286.
26. Socié G. Allogeneic BM transplantation for the treatment of aplastic anemia: current results and expanding donor possibilities. Hematology Am Soc Hematol Educ Program. 2013;2013:82-86.